Ionis Pharmaceuticals, Inc. Common Stock (IONS)
Ionis Pharmaceuticals, Inc. is a biotechnology company specializing in the discovery and development of RNA-targeted therapeutics. Founded in 1989, the company focuses on using antisense technology to develop medicines for various diseases, including neurological, rare, and severe conditions. Ionis is known for its innovative approach to addressing unmet medical needs through gene-silencing strategies.
Company News
Antisense oligonucleotide (ASO) therapeutics are emerging as a promising treatment approach for rare genetic and neuromuscular disorders, with over 70 pharmaceutical companies actively developing 90+ pipeline therapeutics targeting specific genetic mechanisms.
The FDA approved Ionis Pharmaceuticals' Dawnzera, the first RNA-targeted medicine for preventing hereditary angioedema (HAE) attacks in patients 12 and older, demonstrating significant attack rate reduction in clinical trials.
Ionis Pharmaceuticals, a leader in RNA-targeted drug discovery, reported better-than-expected revenue and a smaller-than-expected loss in Q4 2024. The company's recent product launches, including Wainua and Tryngolza, contributed to the positive results, and it plans to continue investing in its pipeline and product launches in 2025.
AstraZeneca reported strong Q2 results, beating estimates for earnings and sales. The company's key drugs like Tagrisso, Ultomiris, Farxiga, and Calquence performed well, while Lynparza and Imfinzi sales were slightly weak. AstraZeneca raised its sales and earnings growth expectations for the year, citing a strong first-half performance.
Leerink Partners upgraded Ionis Pharmaceuticals' stock from Market Perform to Outperform, citing the company's focus on wholly-owned assets like olezarsen and donidalorsen, which are nearing commercialization.